問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of General Internal Medicine

Division of Otolaryngology

Division of Others-

更新時間：2023-09-19

黃昭誠
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃昭誠

List

12Cases

2018-05-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-12-14 - 2024-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-03-01 - 2029-04-01

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2018-01-15 - 2029-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

2018-05-31 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-01-01 - 2027-07-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2026-08-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2025-07-01 - 2029-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2016-09-19 - 2019-08-23

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated6Sites

鍾飲文
Kaohsiung Municipal Gangshan Hospital

未分科

2020-10-01 - 2022-10-14

Phase II/III

A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)

  • Condition/Disease

    Head and Neck Squamous-Cell Carcinoma

  • Test Drug

    NKTR 214

Participate Sites
6Sites

Not yet recruiting6Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB